MVRBF News and Press, Medivir B From 12/11/20

Medivir strengthens its business development possibilities through a renegotiated agreement with TetraLogic regarding birinapant STOCKHOLM , Dec. 11, 2020 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today that Medivir AB ("Medivir" or "the Comp...

Medivir appoints Dr. Tom Morris as interim Chief Medical Officer PR Newswire STOCKHOLM, Oct. 5, 2020 STOCKHOLM , Oct. 5, 2020 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today it has appointed Dr. Tom Morris as interim Chief Medical ...

STOCKHOLM , July 3, 2020 /PRNewswire/ --  Medivir AB (Nasdaq Stockholm: MVIR) today announced that the European Commission, in accordance with the opinion from the European Medicines Agency (EMA), has granted orphan medicinal product designation in the EU for MIV-818 for the trea...

Medivir AB ( OTC:MVRBF ) has appointed Yilmaz Mahshid as the new CEO, succeeding Uli Hacksell. More news on: Medivir AB (publ), Medivir AB ADR, Read more ...

STOCKHOLM , May 6, 2020 /PRNewswire/ --  Medivir AB (Nasdaq Stockholm: MVIR)  today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to MIV-818 for the treatment of patients with hepatocellular carcinoma (HCC), the most common ...

HUDDINGE, Sweden , May 5, 2020 /PRNewswire/ --  Positive results for MIV-818 and continued tempo in business development January - March Significant events during the quarter Data from the phase Ia study with MIV-818 in liver cancer patients presented at Medivir's R&a...

STOCKHOLM , April 30, 2020 /PRNewswire/ --   Medivir AB (Nasdaq Stockholm: MVIR)  today announced that it has received positive opinion from the Committee for Orphan Medicinal Products on orphan medicinal product designation in the EU for MIV-818 for the treatment of patien...

STOCKHOLM , March 16, 2020 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR)  today announced that it has entered into a license agreement with US biotech company Tango Therapeutics for one of Medivir's preclinical research programs. Under the terms of the agreement, Medivir will ...

STOCKHOLM , March 10, 2020 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that the first patient with advanced liver cancer has been dosed in the phase Ib study of MIV-818. The MIV-818 phase I study (NCT03781934) consists of two parts: (i) the already completed...

Medivir AB ( OTC:MVRBF ): Q4 GAAP EPS of -SEK1.32. Revenue of SEK1.4M (-89.7% Y/Y) Press Release More news on: Medivir AB (publ), Medivir AB ADR, Earnings news and commentary, Tech stocks news, ,